Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
This multicenter, 2-stage, open-label, phase II trial aims to assess the efficacy and safety of dacomitinib in adult patients with recurrent Glioblastoma (GBM) with EGFR gene amplification and/or EGFRvIII mutation.
Glioblastoma|Brain Tumor, Recurrent
DRUG: PF-299804 (Dacomitinib)
Progression-free Survival (PFS) at Six Months (PFS6m), Percentage of patients who have progressed / no progress after 6 months of treatment in each of the two cohorts., Baseline and after 6 months
Safety and Tolerability of Oral Administration of PF-00299804., Type, incidence, severity, frequency, severity and relationship with IMP of reported adverse events, physical examinations and laboratory tests. Toxicity will be classified and tabulated by NCI-CTCAE v 4.0., Up to 42 months|Anti-tumor Response, According to RANO criteria. Based on neurological symptoms, doses of dexamethasone and radiological response, assessed by the PI of each center. There will be central review of MRI., Baseline and every 12 weeks|Overall Survival (OS), Time from randomization to death by any cause., Up to 42 months|Response Duration, Time from first objective response up to disease progression according RANO (in patients with objective responses)., Baseline and every 12 weeks|Changes in the Use of Glucocorticoids, Percentage of patients decreasing doses of corticosteroids during treatment., Baseline and every 12 weeks|Changes in Neurological Status., By means of minimental test, it will be determined the changes in neurological status of patients., Baseline and every 12 weeks
This multicenter, 2-stage, open-label, phase II trial aims to assess the efficacy and safety of dacomitinib in adult patients with recurrent Glioblastoma (GBM) with EGFR gene amplification and/or EGFRvIII mutation.